ACP-105
Aliases: ACP105
Last verified: 2026-09-23
The short version
A SARM from the Acadia program — anabolic potential with reportedly milder suppression; preclinical data also show cognitive/neural effects. Key fact: No controlled human trials exist. Everything known about ACP-105 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A SARM from the Acadia program — anabolic potential with reportedly milder suppression; preclinical data also show cognitive/neural effects.
Mechanism of action
Selective AR agonism; additional CNS actions (preclinical).
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for ACP-105. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 5–15 mg/day. Described as a "milder RAD-140": modest mass gains with little suppression; experiences limited.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Described as a "milder RAD-140": modest mass gains with little suppression; experiences limited.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
5–15 mg oral daily; a minority of vendor listings go to 20 mg.
- Cycle:
- 8 weeks.
- Break:
- 4 weeks; milder suppression means PCT is debated rather than assumed.
Marketed as a 'milder RAD-140' — modest mass gains with comparatively little suppression. The human experience base is small, and the cognitive-angle marketing has no human data behind it.
Human evidence
No controlled human trials exist. Everything known about ACP-105 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical; clinical development never advanced.
Known risks
- Unknown in humans; presumed mild suppression.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.